aml: Remission Times for Acute Myelogenous Leukaemia

amlR Documentation

Remission Times for Acute Myelogenous Leukaemia

Description

A clinical trial to evaluate the efficacy of maintenance chemotherapy for acute myelogenous leukaemia was conducted by Embury et al. (1977) at Stanford University. After reaching a stage of remission through treatment by chemotherapy, patients were randomized into two groups. The first group received maintenance chemotherapy and the second group did not. The aim of the study was to see if maintenance chemotherapy increased the length of the remission. The data here formed a preliminary analysis which was conducted in October 1974.

Usage

data(aml)

Format

A data frame with 23 observations on the following 3 variables.

time

The length of the complete remission (in weeks).

cens

An indicator of right censoring. 1 indicates that the patient had a relapse and so 'time' is the length of the remission. 0 indicates that the patient had left the study or was still in remission in October 1974, that is the length of remission is right-censored.

group

The group into which the patient was randomized. Group 1 received maintenance chemotherapy, group 2 did not.

Source

Miller, R.G. (1981) Survival Analysis. John Wiley: New York. Page 49.

References

Embury, S.H, Elias, L., Heller, P.H., Hood, C.E., Greenberg, P.L. and Schrier, S.L. (1977) Remission maintenance therapy in acute myelogenous leukaemia. Western Journal of Medicine, 126, 267–272.


SMPracticals documentation built on May 29, 2024, 12:19 p.m.